Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1091 Linsitinib (OSI-906) <1 mg/mL 84 mg/mL <1 mg/mL
S1034 NVP-AEW541 <1 mg/mL 88 mg/mL <1 mg/mL
S1093 GSK1904529A <1 mg/mL 124 mg/mL <1 mg/mL
S1088 NVP-ADW742 <1 mg/mL 10 mg/mL 3 mg/mL
S1012 BMS-536924 <1 mg/mL 96 mg/mL <1 mg/mL
S1234 AG-1024 <1 mg/mL 61 mg/mL <1 mg/mL
S2703 GSK1838705A <1 mg/mL 107 mg/mL <1 mg/mL
S1124 BMS-754807 <1 mg/mL 92 mg/mL 92 mg/mL
S8003 PQ 401 <1 mg/mL 32 mg/mL <1 mg/mL
S7106 AZD3463 <1 mg/mL 24 mg/mL <1 mg/mL
S8228 NT157 <1 mg/mL 82 mg/mL 82 mg/mL
S7668 Picropodophyllin (PPP) <1 mg/mL 82 mg/mL 1 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations

Linsitinib (OSI-906)

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.



NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.



GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.



NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.



BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.



AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).



GSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases.



BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.


PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.



AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.



NT157, a selective inhibitor of IRS-1/2(insulin receptor substrate), has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival.


Picropodophyllin (PPP)

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).

Tags: IGF-1R pathway | IGF-1R cancer | IGF-1R signaling | IGF-1R pathway | IGF-1R phosphorylation | IGF-1 receptor signaling | IGF-1R signaling pathway | IGF-1 receptor signaling pathway | IGF-1R inhibitor review